Lipoprotein-associated phospholipase A2, fasting blood glucose, and granulocyte count for

A retrospective case-control study of 295 individuals (206 CHD patients and 89 non-CHD controls) by Zhanxiang Lin, published in 2026. It evaluates the diagnostic value of serum Lp-PLA2, fasting blood glucose, and granulocyte count for coronary heart disease, including age- and sex-specific thresholds.

Use Cases

• Developing diagnostic models for coronary heart disease based on serum Lp-PLA2 levels.
• Evaluating the combined diagnostic performance of inflammatory and metabolic biomarkers.
• Establishing preliminary age- and sex-specific cutoff values for clinical biomarkers.
• Training logistic regression models using independent risk factors like hypertension and diabetes status.

Strengths

• Contains data for 295 individuals, providing a basis for model development.
• Includes specific, validated cutoff values (e.g., 137 μg/L for Lp-PLA2) and AUC metrics (e.g., 0.913 for Lp-PLA2).
• Explicitly evaluates a combined model achieving an AUC of 0.917 with sensitivity of 0.956.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• Data may reflect bias inherent to the specific retrospective study design and source platform.

Provenance

Source

Zhanxiang Lin via figshare

Collection Method

Retrospective case-control study with serum biomarker measurement and multivariable logistic regression.

Freshness

Last updated 2026-05-24 15:00:03; freshness should be verified.